← Eichor
Study identifier: NCT07316062 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

Condition: Non-Small-Cell Lung  ·  Sponsor: AstraZeneca

PhaseN/A
Planned participants3000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (1)

Research SiteBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07316062